Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jul 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the combination of two medications, VX-993 and metformin, affects how each drug works in the body. The researchers want to understand if taking these medications together is safe and how they interact with one another. This study is currently looking for healthy adults aged between 18 and 65 who meet certain health criteria, such as having a body mass index (BMI) between 18.0 and 32.0 and weighing more than 50 kilograms. Participants should also be nonsmokers or ex-smokers who haven’t smoked for at least three months before starting the trial.

If you choose to participate, you will be monitored closely for any side effects and how your body processes the medications. This is an important study that could help improve understanding of how these drugs work together, which may be beneficial for future treatments. It's essential to know that if you have had any recent illnesses or have health conditions that might affect how your body absorbs or processes drugs, you may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) of 18.0 to 32.0 Kilogram per square meter (kg/m\^2)
• • A total body weight of more than (\>) 50 Kg
• • Nonsmoker or ex-smoker for at least 3 months before the first study drug dose
• Key Exclusion Criteria:
• • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
• • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
• • Other protocol defined Inclusion/Exclusion criteria may apply.